Clinical trials Endang W. Hoyaranda, President Director of Prodia Group, speaks about the ongoing challenges of clinical trials in Indonesia, especially in remote medical communities, and why changing the mindset from ‘guinea pig’ testing to medical advancement opportunities is key to changing the landscape of clinical trials in the country. Although Prodia…
Distribution The CEO of independent distributor Anugerah Pharmindo Lestari (APL) discusses the current market trends in Indonesia for distribution, which involve local pharma companies keeping their distribution in-house, and how his company, number one in the independent market, is working to break the trend of distribution in the country. A key challenge…
Generics The CEO of Metiska Farma talks about coming back to Indonesia after studying in the US at Berkeley and MIT, to take over the company, and the company’s strategy of adding value through a portfolio of generics and OTC products. Can you begin by giving a brief introduction of Metiska…
CSR The President Director of Novartis Indonesia talks about the strong competition his company faces from local generics manufacturers, and his perspectives on the other challenges currently facing his company in the Indonesian market. You mentioned earlier that the current 20 percent growth of Novartis Indonesia is still possible because the…
Government Regulation The president of Brancorth Medical talks about the challenges of the start-up med tech scene in Canada, turning innovation into corporate success, and the role of the government in creating the right environment for medical devices companies to flourish in Canada. You started Brancorth Medical in 2011, having spent an…
BIOQuébec Mr. Lebrun discusses the role that BIOQuébec plays in the industry, its aims in representing several sectors and their plans for the coming years. Could you introduce BIOQuébec and its main priorities to our readers? BIOQuébec is a voluntary trade association representing Québec-based life sciences organizations. Its membership includes biotechnology…
Botanical drugs The Chairman and CSO of TCM Biotech offer perspectives on the potential of botanical drugs, and chart their biotech company’s trajectory in bringing these drugs to both the Chinese and US markets. Mr. Hsu, can you please introduce our readers to yourself and to TCM Biotech? Shining Hsu (SH): I…
UAE Jan Van der Goten, GCC Managing Director of Janssen UAE, talks about his experience at Janssen GCC as regional manager, how collaboration with other companies in the industry will bring about better results for the issue of diabetes, and why this may be harder to accomplish than expected. You…
UAE Samer Al Hallaq, Gulf President of AstraZeneca, speaks about the company’s strategy to align its portfolio with the increasing presence of lifestyle diseases like diabetes, and how innovation is the driving force behind continued growth for the future. Let’s begin by speaking a little bit about AstraZeneca’s global focus…
UAE Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the industry with the government and educational institutes will help overcome this problem before it’s too late. Our approach to…
UAE Ahmad Tabari, Managing Director of Pharmax, gives his insight into the regions major challenges, why he thinks that, regardless of the amount of money the government invests, the problem of a small talent pool in the industry will not go away quickly or easily, and Pharmax’s strategy to overcome this…
UAE Ashraf Allam, Regional Managing Director of Amgen, talks about the main challenges the company has faced, the benefit of building a company in the UAE, and the growth strategy of Amgen—past, present and future. Amgen is a relative newcomer to the region having only established is operations in 2006.…
See our Cookie Privacy Policy Here